GLP-1 Peptide Synthesis CDMO Market Research Report with Forecast 2025 to 2034
Share With :
Global GLP-1 Peptide Synthesis CDMO Market Size is predicted to grow at a 12.7 % CAGR during the forecast period for 2025 to 2034.
GLP-1 Peptide Synthesis CDMO Market, Share & Trends Analysis Report, By Synthesis Technology (Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), Group-Assisted Purification Peptide Synthesis (GAP-PS), Hybrid Technology, Recombinant DNA Technology), By Service Type (Analytical and Process Development, Large-Scale Production, Custom Peptide Synthesis, Peptide Modification, Purification Technology, Formulation Development, Regulatory Support, Packaging and Labeling, Pre-Formulation and Registration Batches), By Scale of Operation, By End-User, By Region, and Segment Forecasts, 2025 to 2034.
GLP-1 peptide synthesis CDMOs specialize in GLP-1 peptide synthesis, offering services from research-grade to GMP-compliant production for pharmaceutical applications.
GLP-1 (Glucagon-Like Peptide-1) is a peptide hormone synthesized from the proglucagon gene in intestinal L-cells and certain neurons. It plays a crucial role in regulating blood sugar levels by stimulating insulin release and inhibiting glucagon secretion.
Advanced techniques such as solid-phase peptide synthesis (SPPS), solution-phase synthesis, or hybrid methods are used to produce GLP-1 peptides. These peptides can be manufactured at various scales, ranging from small research batches to large-scale commercial production, ensuring their availability for both scientific and therapeutic applications. Drug companies often prefer to outsource GLP-1 peptide synthesis to CDMOs due to the complexity and scalability challenges associated with this process as CDMOs offer specialized expertise, advanced infrastructure, and cost-effective solutions for both research and large-scale production of GLP-1 peptides.
Factors such as surging market demand for the global GLP-1 receptor agonists, therapeutic expansion of GLP-1 Beyond diabetes in obesity, cardiovascular diseases, and neurodegenerative disorders treatment, sophisticated synthesis requirements for GLP-1 peptides (e.g., solid-phase peptide synthesis or hybrid approaches), high-purity standards, and impurity control, shortages of high-quality raw materials and the need for cost-effective, sustainable manufacturing and stringent FDA and EMA requirements for GMP-grade peptides fuel the need for scalable, high-quality peptide production and drug manufacturing companies to outsource manufacturing to the GLP-1 peptide synthesis CDMOs.
The growing global prevalence of type 2 diabetes and obesity has significantly increased demand for GLP-1 receptor agonists such as semaglutide, liraglutide, and tirzepatide, which are known for their ability to manage blood glucose levels, support weight loss, and improve cardiovascular outcomes. This surge in demand is driving the need for large-scale peptide production, making CDMOs essential partners in this process. As peptides gain popularity for their high selectivity, potency, and favorable safety profiles, GLP-1 analogues have emerged as a key segment within the peptide therapeutics market, encouraging pharmaceutical companies to outsource their production to specialized CDMOs increasingly.
The GLP-1 peptide synthesis CDMO market is segmented based on synthesis technology, service type, scale of operation, and end-user. Based on synthesis technology, the market is segmented into solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), group-assisted purification peptide synthesis (GAP-PS), hybrid technology, and recombinant DNA technology.
Based on the type of service, the market is divided into analytical and process development, large-scale production, custom peptide synthesis, peptide modification, purification technology, formulation development, regulatory support, packaging and labeling, pre-formulation, and registration batches. Based on the scale of operation, the market is divided into clinical-scale manufacturing, commercial-scale manufacturing, and pilot-scale manufacturing. Based on the end-user, the market is divided into pharmaceutical companies, biotechnology companies, and research institutions.
The solid-phase peptide synthesis (SPPS) segment is expected to have the highest growth rate during the forecast period. GLP-1 analogues, such as semaglutide and other long-chain, structurally complex peptides, are best synthesised via solid-phase peptide synthesis (SPPS). Compared to solution-phase techniques, it permits the gradual addition of amino acids, providing for more control and oversight. To improve the stability, bioactivity, and pharmacokinetics of GLP-1 analogues, SPPS also supports the addition of non-natural amino acids, PEGylation, lipidation, and other chemical modifications. Due to these qualities, SPPS is a crucial platform for the creation and manufacture of future-generation GLP-1 receptor agonists.
The large-scale production segment is expected to dominate the market. There is a demand for kilogram-scale, GMP-compliant peptide manufacturing, as many GLP-1 analogues have progressed from clinical development to full commercialization. Large-scale CDMOs are crucial for providing reliable, superior, and legally compliant manufacturing at industrial scales. The cost-per-gram of peptide active pharmaceutical ingredients (APIs) is significantly decreased by economies of scale made possible by large-scale manufacture. Pharmaceutical businesses seeking dependable and efficient manufacturing partners find CDMOs with automated solid-phase peptide synthesis (SPPS) systems and optimized batch processes to be highly appealing, as they can offer competitive pricing and expedited turnaround times.
North America, particularly the US, is one of the largest markets for GLP-1 receptor agonists such as Ozempic, Wegovy, and Mounjaro. The demand for GLP-1 analogue manufacture is greatly influenced by the fact that the US leads the world in pharmaceutical research and development, particularly in the fields of diabetes and obesity treatments. The region's CDMOs are favored partners for the clinical and commercial-scale manufacturing of GLP-1 peptides due to their sophisticated infrastructure and strict adherence to FDA standards. The market in North America is expected to increase due to its sophisticated manufacturing capabilities, robust pharmaceutical demand, and concentration of top-tier CDMOs that can support large-scale clinical and commercial peptide production.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 12.7 % from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Synthesis Technology, By Service Type, By Scale of Operation, By End-User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
| Competitive Landscape | Bachem Holding AG, CordenPharma, PolyPeptide Group, AmbioPharm, CPC Scientific, CSBio, Creative Peptides, Lonza, Aurisco Pharmaceutical, Hybio Pharmaceuticals, Chinese Peptide Company, Neuland Laboratories, Divis Laboratories, Supriya Lifescience, Allsino Pharmaceutical Co. Ltd |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global GLP-1 Peptide Synthesis CDMO Market - By Synthesis Technology
Global GLP-1 Peptide Synthesis CDMO Market – By Service Type
Global GLP-1 Peptide Synthesis CDMO Market – By Scale of Operation
Global GLP-1 Peptide Synthesis CDMO Market – By End-User
Global GLP-1 Peptide Synthesis CDMO Market – By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.